レイノーの現象における強化されたコレニン学的皮膚血管拡張
1Peripheral Vascular Section, Evans Memorial Department of Clinical Research, Boston University Medical Center, MA.
Circulation
|March 1, 1994
まとめ
レイノード症候群の患者は,指先と前腕の皮膚の血管拡張反応がメタコリンに対して強化され,皮膚血管の反応が増加することを示唆しています. これは,レイノ現象における血管の病理生理学と関係しているのかもしれない.
科学分野:
- 血管生理学 血管の生理学
- 皮膚科 皮膚科について
- 心血管研究に関する研究.
背景:
- レイノード症候群は,過度の血管収縮が特徴です.
- 血管拡張機能を理解することは,この状態の管理に不可欠です.
- 内皮に依存し,内皮に依存しない血管拡張剤は,血管機能を評価する鍵です.
研究 の 目的:
- レイノード現象の患者における血管拡張機能の判定.
- エンドセリウム依存型 (メタコリン) と非依存型 (ナトリウムニトロプロシド) 血管拡張剤に対する反応を比較する.
- レイノード現象の患者の反応性高血症を調査する.
主な方法:
- メタコリンとナトリウムニトロプロシドの動脈内注入.
- 指先と前腕の血流のための静脈閉塞プレチスモグラフィー.
- 前腕の皮膚の血流のレーザー・ドップラー流量計.
- 動脈閉塞後の反応性高血症の測定.
主要な成果:
- レーノード症候群の患者は,対照群とは異なり,メタコリンによる指先の血流の有意な増加を示した.
- 前腕の皮膚の血流は,レイノーの患者のメタコリンに対するより大きな血管拡張反応を示した.
- 前腕の全血流量と反応性高血症の反応は,両方の血管拡張剤のグループ間で類似していました.
結論:
- レイノード症候群は,指先と前腕の皮膚における血管拡張反応の強化と関連しています.
- これは,レイノード症候群において,内皮刺激に対する皮膚血管の反応性が高まっていることを示唆している.
- 根本的なメカニズムは,血管と関連した皮膚血管の一般的な異常を伴う可能性があります.
関連する概念動画
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...


